查詢結果分析
來源資料
相關文獻
- 反覆流產及栓塞症的潛在元兇--抗磷脂質症候群
- 抗磷脂質症候群的血栓症(Antiphospholipid Syndrome)
- 抗磷脂質症候群
- Successful Delayed Thrombolytic Therapy in a Patient with Massive Pulmonary Embolism
- 以動脈注射血栓溶劑治療急性缺血性腦中風:七例報告
- 成功使用血栓溶解劑治療急性缺血性腦中風:一病例報告暨文獻回顧
- 血栓閉塞性脈管炎病案一則
- 靜脈血栓性栓塞的預防及治療概念
- 血栓症之新發現--抗磷脂抗體症候群
- A Comparative Study of Urokinase and Heparin in the Treatment of Deep Vein Thrombosis
頁籤選單縮合
題 名 | 抗磷脂質症候群=Antiphospholipid Syndrome |
---|---|
作 者 | 蔡憶萱; 楊璦瑜; | 書刊名 | 藥學雜誌 |
卷 期 | 35:1=138 2019.03[民108.03] |
頁 次 | 頁38-43 |
分類號 | 415.695 |
關鍵詞 | 抗磷脂質症候群; 血栓; Antiphospholipld syndrome; |
語 文 | 中文(Chinese) |
中文摘要 | 抗磷脂質症候群是一種自身免疫性炎症性疾病,與動靜脈血栓、妊娠流產相關。 依是否有伴隨其他免疫疾病,分為原發性和繼發性抗磷脂質症候群。其病理生理機制 包括抗磷脂質抗體誘導的細胞活化,抑制抗凝血劑和纖維蛋白溶解系統,以及補體激 活。 治療的首要重點為預防血栓的形成。Warfarin、heparin (肝素)、抗血小板劑是 抗磷脂質症候群血栓的標準治療。發生急性血栓事件首選藥物為 heparin,症狀穩定 後低分子量肝素取代傳統肝素作為標準療法。血栓控制目標為國際標準凝血時間比 (international normalized ratio;INR) 2.0-3.0,如果再次出現血栓,則須提高 INR 控制 目標值。治療上以抗凝治療作為長期照護,隨著近來疾病機轉越來越被了解,新的治 療藥物例如 hydroxychloroquine、statin、rituximab 等都在臨床研究中顯示出前景。 |
英文摘要 | Antiphospholipid syndrome (APS) is an autoimmune, inflammatory disorder associated with venous, arterial thrombosis, pregnancy loss. This disorder is differentiated into primary and secondary antiphospholipid syndromes based on its without or with complication of other autoimmune disorders. Pathophysiologic mechanisms in APS include antiphospholipid antibody (aPL) induced cellular activation, inhibition of natural anticoagulant and fibrinolytic systems, and complement activation. The mainstay of treatment for patients is prevention of thrombosis. Warfarin, heparin and/ or antiplatelet drugs are the main medications for APS thrombosis. For acute thrombosis, the first choice is heparin, which is then replaced by low molecular weight heparin (LMWH) for stable condition. Standard medication currently is to keep INR 2.0-3.0, and a higher controlled INR if thrombosis recur. Long term anticoagulation is the principle of treatment for thrombotic APS. The knowledge about APS is advanced in recent years. New therapeutic agents such as hydroxychloroquine, statins, rituximab etc. have shown promise in clinical studies. |
本系統中英文摘要資訊取自各篇刊載內容。